| Date Filed | Type | Description |
| 08/18/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 08/17/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/16/2023 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 05/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/29/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/29/2023 |
8-K
| Quarterly results |
| 03/29/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 12/07/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/10/2022 |
8-K
| Quarterly results|
Docs:
|
"Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update SAN CARLOS, Calif., Nov. 10, 2022 -- SAN CARLOS, Calif., November 10, 2022 -- Atreca, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2022 and provided an overview of recent developments. "The third quarter was a productive period, as we continue to enroll patients in the Phase 1b trial of ATRC-101,” said John Orwin, Chief Executive Officer of Atreca. “We remain encouraged by the association we see between clinical activity and target expression, the durability of the clinical activity observe..." |
|
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/08/2022 |
8-K
| Quarterly results |
| 06/14/2022 |
8-K
| Quarterly results |
| 06/01/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
8-K
| Quarterly results |
| 05/11/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 04/28/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/05/2022 |
8-K
| Entry into a Material Definitive Agreement, Other Events Interactive Data |
| 03/03/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/03/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G/A
| Redmile Group, LLC reports a 2.6% stake in Atreca, Inc. |
| 02/14/2022 |
SC 13G/A
| Boxer Capital, LLC reports a 7.2% stake in Atreca, Inc. |
| 02/14/2022 |
SC 13G/A
| EcoR1 Capital, LLC reports a 0% stake in Atreca, Inc. |
| 02/14/2022 |
SC 13G/A
| EcoR1 Capital, LLC reports a 0% stake in Atreca, Inc. |
| 02/03/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/10/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 11/15/2021 |
SC 13G
| Logos Global Management LP reports a 3.3% stake in Atreca, Inc. |
| 11/02/2021 |
8-K
| Quarterly results|
Docs:
|
"Atreca Reports Third Quarter 2021 Financial Results and Recent Corporate Developments SAN CARLOS, Calif., Nov. 02, 2021 -- Atreca, Inc. , a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent developments. "In the third quarter, we continued to advance our lead program, ATRC-101, following the release of initial summary data from the dose escalation portion of the Phase 1b trial, which supports the further evaluation of ATRC-101 in multiple solid tumor types,” said John Orwin, Chief Executive Officer. “We plan to share additional monotherapy dat..." |
|
|